Kiniksa director exercises options, sells 20,129 Class A shares

Kiniksa Pharmaceuticals International, plc director reports option exercise and share sale.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc director reports option exercise and share sale. On 12/15/2025, the reporting person exercised a share option for 20,129 Class A ordinary shares at an exercise price of $10.36 per share and acquired these shares. On the same date, they sold 20,129 Class A ordinary shares in broker-dealer trades at a weighted average price of $41.51 per share, with individual trade prices ranging from $41.19 to $41.78. After these transactions, the director beneficially owned 12,546 Class A ordinary shares directly, and held 0 derivative securities following the full exercise of the option, which was fully vested and exercisable. The transactions were made under a Rule 10b5-1 trading plan executed on September 11, 2025.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Quart Barry D

Role Director

Sold 20,129 shs ($836K)

Approx. gross sale proceeds $836K

Approx. exercise cost $209K

Type	Security	Shares	Price	Value
Exercise	Share Option	20,129	$0.00	$0.00
Exercise	Class A Ordinary Share	20,129	$10.36	$209K
Sale	Class A Ordinary Share	20,129	$41.51	$836K

Holdings After Transaction: Share Option — 0 contracts (Direct); Class A Ordinary Share — 12,546 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.
2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.19 and $41.78. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. F3. The option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kiniksa Pharmaceuticals (KNSA) report on this Form 4?

The filing reports that a director exercised a share option for 20,129 Class A ordinary shares at an exercise price of $10.36 and, on the same day, sold 20,129 Class A ordinary shares in the open market.

What prices were involved in the Kiniksa Pharmaceuticals (KNSA) insider’s trades on 12/15/2025?

The director exercised options at an exercise price of $10.36 per share and sold shares at a weighted average sales price of $41.51 per share, with individual trades executed between $41.19 and $41.78.

How many Kiniksa Pharmaceuticals (KNSA) shares does the insider own after the reported transactions?

Following the reported transactions, the director beneficially owned 12,546 Class A ordinary shares with direct ownership and held 0 derivative securities after the option exercise.

Was the Kiniksa Pharmaceuticals (KNSA) insider trade under a Rule 10b5-1 plan?

Yes. The filing states that the transaction was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person on September 11, 2025.

What type of derivative security did the Kiniksa Pharmaceuticals (KNSA) director exercise?

The derivative security was a share option covering 20,129 Class A ordinary shares with an exercise price of $10.36 per share, which was fully vested and exercisable and resulted in 0 options remaining after exercise.

What is the insider’s relationship to Kiniksa Pharmaceuticals (KNSA)?

The reporting person is a director of Kiniksa Pharmaceuticals International, plc, and the Form 4 is filed by one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/17/2025 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quart Barry D

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INTERNATIONA

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON X0 W1J 7NJ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	12/15/2025		M(1)		20,129	A	$10.36	32,675	D
Class A Ordinary Share	12/15/2025		S(1)		20,129	D	$41.51(2)	12,546	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$10.36	12/15/2025		M(1)			20,129	(3)	02/29/2028	Class A Ordinary Shares	20,129	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.19 and $41.78. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.